Stock analysts at StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Price Performance
NASDAQ:RDHL opened at $3.85 on Tuesday. RedHill Biopharma has a 1-year low of $3.01 and a 1-year high of $20.27. The business’s 50-day moving average price is $5.87 and its two-hundred day moving average price is $15.06.
Hedge Funds Weigh In On RedHill Biopharma
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC acquired a new stake in RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.20% of the company’s stock.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Read More
- Five stocks we like better than RedHill Biopharma
- When to Sell a Stock for Profit or Loss
- Buffett’s on the Sidelines – Should You Follow?
- What Are Some of the Best Large-Cap Stocks to Buy?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What Does a Stock Split Mean?
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
